” While the Ricaurte story was unfolding, MAPS lastly gained FDA indication-off over a protocol for human trials of copyright for a remedy for PTSD, but only following it purchased a $one million insurance policy plan to indemnify the overview board.However for drug reformers, nonetheless, the “shop” is not – nevertheless – the results of